Eli Lilly (LLY) earnings Q3 2025
A sign with the company logo sits outside Eli Lilly’s headquarters in Indianapolis, Indiana, on March 17, 2024.
Scott Olson | Getty Images
Eli Lilly On Thursday, the company reported third-quarter earnings and revenue that beat estimates and raised its full-year outlook as it continued to see strong demand for its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro.
Here’s what Eli Lilly reported for the third quarter compared to Wall Street’s expectations, based on a survey of analysts by LSEG:
- Earnings per share: $7.02 adjusted, expected $5.69
- Revenues: 17.60 billion dollars, while the expectation was 16.01 billion dollars
The results come like this Eli Lilly It is trying to maintain its edge over chief rival Novo Nordisk in the emerging market for a class of obesity and diabetes drugs called GLP-1.
This story is developing. Please check back for updates.
